Interplay between miR-17-5p and MALAT-1 shapes the cytokine storm in triple negative breast cancer (TNBC) tumor microenvironment

A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma

“…LncRNA H19 is another lncRNA that has been recently added to the list of emerging immunomodulatory lncRNAs through manipulating the expression profile of NK activating ligands on tumor cells and CD155 expression in several malignancies [ 11 , 30 , [32] , [33] , [34] , [35] ]. Furthermore, H19 has also been linked to tumor cell development, hypoxic stress, macrophage activation, chemotaxis, and differentiation [ 36 , 37 ].…”

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer

“…Such strategies represent a vicious evasion mechanism that obverts immune responses against tumors [15] . Another tactic that has been extensively studied by our research group is hijacking the immune-surveillance by TNBC tumors via genetic and epigenetic alterations which modulate several components of TME, consequently suppressing the infiltrating immune cellular activity [16] , [17] , [18] , [19] , [20] , [21] , [22] . Accordingly, re-sensitizing the cytotoxic immune cells at the TME through reversing these immunoediting processes is considered a milestone towards the development of more effective immunotherapeutic therapeutic modality.…”